Textiles functionalized with antiviral agents are intended to reduce the risk of transmission of pathogens, particularly in a medical environment. These antiviral properties must be carefully tested and verified in laboratory tests. The biological testing laboratory of the German Institutes of Textile and Fiber Research Denkendorf has examined antiviral activities with coronaviruses as part of a research project on textiles for infection control.

Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support.

Many people are infected with the Epstein-Barr virus (EBV), and most are unaware of it. However, EBV can sometimes cause cancer, and this pathogen also appears to play an important role in multiple sclerosis and other autoimmune diseases. Researchers have discovered that EBV increases the ability of infected immune cells to migrate. In this way, the pathogen promotes its spread in the body – a discovery that may have therapeutic implications.

New treatment methods: DNA origami-based nanodevices precisely control immune response - 24/04/2025

Bottom-up synthetic immunology for novel therapeutic approaches

Modern therapies for combating cancer and infectious diseases increasingly leverage the body’s own immune system. Several research groups at Heidelberg University are using innovative bottom-up approaches in synthetic immunology to develop new treatment methods that can control the immune response more precisely than previously possible.

Researchers from the universities in Konstanz and Vienna discover a new class of antibiotic that selectively targets Neisseria gonorrhoeae, the bacterium that causes gonorrhoea. These substances trigger a self-destruction program, which also operates in multi-resistant variants of the pathogen. The novel findings are published in the current issue of Nature Microbiology.

Stomach ulcers, gastritis and even stomach cancer are often the result of an infection with Helicobacter pylori. If the bacterium remains unrecognised for a long time, this can have serious consequences. Researchers have now developed a miniaturisable sensor system for the mobile analysis of breath that is effective, fast and inexpensive. The research team uses a biological survival trick of the stomach germ to detect the bacterium.

University of Tübingen research team shortens the search for attackers that can wipe out multiresistant pathogens – with the aim of treating infections without antibiotics

Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication. Scientists work on new approaches to combating highly dangerous viral diseases such as yellow fever or Lassa fever. The European Union is supporting the project over a period of five years to the tune of just under eight million euros.

In collaboration with Heraeus, the German Institutes of Textile and Fiber Research (DITF) are developing fibers and textiles with a novel infection protection system. The basis is an antimicrobial mechanism of action licensed from Heraeus and marketed under the name AGXX. The goal of the collaboration is to optimally integrate the AGXX technology into textile finishes and coatings and to incorporate it into fiber-spinnable polymers.

Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging and re-emerging viruses.

Cell division, cell differentiation, cell repair and cell death play fundamental roles in the human organism, its development, health and reproduction. Cellular transformation processes are governed by two regulatory mechanisms: chromatin modifications and cell signaling networks. The EpiSignal Research Training Group sheds light on the hitherto little-researched interplay between these two complex systems.

Heidelberg scientist Dr Venera Weinhardt has received an ERC Synergy Grant for a pioneering biomedical research project. The European Research Council (ERC) is granting this funding to advance soft X-ray microscopy. This imaging technique along with other innovations will be used to investigate the hepatitis E virus.

Invasive infections such as sepsis require immediate and targeted treatment. Experts from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB and group partners have succeeded in establishing a reconceptualized detection principle that can make a crucial contribution to saving lives through fast, ultra-accurate pathogen identification. They have been chosen to receive the 2024 Stifterverband Science Prize for their efforts.

App for tuberculosis diagnosis - 15/05/2024

"Find-TB" aims to improve access to tuberculosis diagnostics

Globally, the majority of children with tuberculosis remain undiagnosed and therefore untreated because their symptoms are categorised incorrectly. Researchers at Heidelberg University Hospital want to develop an app that analyses medical information, risk factors and local surveillance data to calculate individual risk of infection and test those who might be affected with TB as early as possible.

Professor Claudia Denkinger from Heidelberg University's Faculty of Medicine is leading the international collaborative project "BreathForDiagnosis". Researchers from Germany, Italy, South Africa and Romania are working with an industrial partner from Switzerland to develop user-friendly breath tests for the rapid diagnosis of respiratory infections such as tuberculosis.

Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone.

PhD student at Furtwangen University develops method for faster determination of antibiotic resistance. The increase in antibiotic-resistant pathogens and the associated treatment, which is a major problem in public healthcare facilities, is the subject of a research project at Furtwangen University.

The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform.

With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.

Researchers at the Faculty of Medicine of the University of Freiburg discover key factor in the development of immune cells. New approaches for the treatment of ALPS.

For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.

Computer-assisted genome mining - 04/12/2023

Natural product genomics opens up new avenues in the search for antibiotics

Antibiotic-resistant pathogens are increasingly endangering our health. Since most of the drugs currently in use are based on secondary metabolites produced by bacteria or fungi, the research group of Prof. Dr. Nadine Ziemert in Tübingen is developing bioinformatic tools to specifically search the genome of these organisms for previously unknown antimicrobial agents.

University of Tübingen researchers reverse the evolution of a class of antibiotics to gain insights for the development of new drugs.

The progression of multiple sclerosis (MS) can usually be slowed down with medication, but a cure is currently not possible. It is now established that Epstein-Barr viruses are involved in the development of MS. However, it is not known how the pathogens trigger the disease. The European Union is now funding the international research consortium BEHIND-MS as part of its HORIZON Europe program.

Nanoparticles as drug carriers - 09/11/2023

Inhalation of nanocarriers for antibiotics against resistant tuberculosis pathogens

Around ten million people worldwide still contract tuberculosis every year. With an estimated 1.4 million deaths a year, tuberculosis was the world’s deadliest infectious disease until COVID-19. The high mortality rate is down to the sophisticated biology of the pathogen Mycobacterium tuberculosis. A team of researchers from the KIT and the Research Centre Borstel (FZB) has developed a method that aims to outsmart the bacterium once and for all.